Adaptive Biotechnologies (ADPT) Poised for $33.7M Windfall on Genentech Deal Termination
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the must-buy small-cap stocks to invest in.
Adaptive Biotechnologies Corp (ADPT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Viking Global Andreas Halvorsen | 29,993,708 | $349,426,698 | 1.01% | |
| 2. | Rubric Capital Management David Rosen | 6,256,847 | $72,892,268 | -53% | 1.1% |
| 3. | ARK Investment Management Catherine D. Wood | 4,016,485 | $46,792,053 | -49% | 0.34% |
| 4. | Braidwell LP Alex Karnal | 3,863,107 | $45,005,197 | -20% | 1.54% |
| 5. | Driehaus Capital Richard Driehaus | 2,423,590 | $28,234,824 | +13% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 2,500 | $50,000.00 | 2,500 | 2019-07-01 | Filing | |
| $20.00 | 1,000 | $20,000.00 | 1,000 | 2019-07-01 | Filing | |
| $20.00 | 300 | $6,000.00 | 300 | 2019-07-01 | Filing | |
| $20.00 | 400 | $8,000.00 | 400 | 2019-07-01 | Filing | |
| $20.00 | 500 | $10,000.00 | 500 | 2019-07-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.89 | 1,929 | $17,148.81 | 269,581 | 2025-05-16 | Filing | |
| $8.89 | 1,929 | $17,148.81 | 277,396 | 2025-05-16 | Filing | |
| $7.35 | 68,412 | $502,828.20 | 1,279,524 | 2025-05-01 | Filing | |
| $9.00 | 1,698 | $15,282.00 | 1,279,524 | 2025-03-24 | Filing | |
| $7.19 | 36,291 | $260,932.29 | 15,394 | 2025-03-13 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,650,646 | $54,613,664 | 0.03% | |
| 2. | 1,304,609 | $19,516,950 | 0.02% | |
| 3. | 1,239,625 | $18,544,790 | 0.01% | |
| 4. | 522,802 | $7,821,118 | 0.24% | |
| 5. | 432,538 | $6,470,768 | 0.01% |
News See All
10 Must-Buy Small-Cap Stocks to Invest In
Large-cap tech giants have been the catalyst behind the US equity market rallying to record highs.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Adaptive Biotechnologies Second Quarter 2025 Financial Results Conference Call.
Adaptive Biotechnologies Corporation (ADPT) Rose on Solid Results
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. The U.S.
Craig-Hallum Initiates Coverage of Adaptive Biotechnologies (ADPT) stock, Gives Buy
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) is one of the 10 Worst Aggressive Growth Stocks to Buy According to Short Sellers.
10 Worst Aggressive Growth Stocks to Buy According to Short Sellers
According to Morningstar, stocks have experienced a healthy recovery over the past few months. However, the momentum was insufficient to propel the market to a new high for the year.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2025 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2025 Earnings Call Transcript May 1, 2025Adaptive Biotechnologies Corporation beats earnings expectations.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2024 Earnings Call Transcript
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2024 Earnings Call Transcript February 11, 2025Adaptive Biotechnologies Corporation beats earnings expectations.
Why These 15 Stocks Are Skyrocketing in 2025
The market has started to favor smaller companies in 2025, and stocks between $1 billion and $5 billion in market value are attracting renewed interest.
Billionaire Andreas Halvorsen's Top 15 Long-Term Stock Picks
Andreas Halvorsen is a prominent Norwegian hedge fund manager and the co-founder of Viking Global, one of the most successful equity-focused hedge funds in the world.